Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979

International Journal of Cancer

Volumn 103, Issue 1, 2003, Pages 121-125

  Shepard, Robert L ^a   Cao, Jin ^b   Starling, James J ^a   Dantzig, Anne H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemo sensitizer; Multidrug resistance; Zosuquidar

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DAUNORUBICIN; ELACRIDAR; GLYCOPROTEIN P; IODINE 125; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NAVELBINE; PROTEIN; UNCLASSIFIED DRUG; ZOSUQUIDAR;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MEMBRANE; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DIBENZOCYCLOHEPTENES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FETAL VIABILITY; HUMANS; IMMUNOBLOTTING; NEOPLASM PROTEINS; P-GLYCOPROTEIN; QUINOLINES; TUMOR CELLS, CULTURED;

EID: 0037211554     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10792     Document Type: Article

References (36)

1. Litman T, Druley TE, Bates SE. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Mol Life Sci 2001;58:931-59
2. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator LY335979. Cancer Res 1996;56:4171-9.
3. Benet L, Kroetz D, Sheiner L. Ninth edition; the dynamics of drug-absorption, distribution and elimination. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics: Pharmacokinetics, 9th Ed., New York: McGraw Hill, 1996, 3-27.
4. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999;290:854-62.
5. Koeller J, Eble M. Mitoxantrone: A novel anthracycline derivative. Clin Pharmacy 1988;7:574-81.
6. Lenk H, Müller U, Tanneberger S. Mitoxantrone: Mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 1987;7:1257-64.
7. Niitani H. Navelbine (Vinorelbine): A review of its antitumor activity and toxicity in clinical studies. Jpn J Cancer Chemother 1999;26:1495-1507.
8. Vogel CL. Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: A review. Semin Oncol 1995;22:61-5.
9. Wiseman LR, Spencer CM. Mitoxantrone: A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997;10:473-85.
10. Adams DJ, Knick VC. P-glycoprotein mediated resistance to 5′-noranhydro-vinblastine (Navlebine). Invest New Drugs 1995;13:13-21.
11. Allikmets R, Schriml LM, Hutchison A, Romano-Spica V, Dean, MA. Human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-9.
12. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70.
13. Miyake K, Mickley L, Litman T, Zhan Z., Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res 1999;59:8-13.
14. Withoff S, de Vries EG, Keith WN, Nienhuis EF, van der Graaf WT, Uges DR, Mulder NH. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer 1996;74:1869-76.
15. Zhou DC, Simonin G, Faussat AM, Zittoun R, Marie JP. Effect of multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. Leukemia 1997;11:1516-22.
16. Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ, Morrow CS. Resistance to mitoxantrone in multidrug-resistant MCF-7 breast cancer cells: Evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res 2001;61:5461-7.
17. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van der Laar A, Litman T, Dean M, Bates SE. Acquired mutations in MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001;61:6635-9.
18. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RCAM, Ruevekamp-Helmers MC, Floot BGJ, Schellens JHM. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-63.
19. He H, Rabindran SG, Greenberger LM, Carter GT. Fumitremorgin C analogs that reverse mitoxantrone resistance in human colon carcinoma cells. Med Chem Res 1999;9:424-37.
20. Rabindran SK, He H, Singh M, Ross DD, Doyle LA, Yang W, Bates SE, Geenberger LM. Fumitremorgin C reverses a novel multidrug resistance mechanism in mitoxantrone-selected cells. Proc Am Assoc Cancer Res 1999;40:315-6.
21. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59:4237-41.
22. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999;146:117-26.
23. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-602.
24. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 1998;247:859-63.
25. Pfister JR, Makra F, Muehldorf AV, Wu H, Nelson JT, Cheung P, Bruno NA, Casey SM, Zutshi, N, Slate DL. Methanodibenzosuberylpiperazines as potent multidrug resistant reversal agents. Bioorg Med Chem Lett 1995;5:2473-6.
26. Slate DL, Bruno NA, Casey SM, Zutshi N, Garvin LJ, Wu H, Pfister JR. RS-33295-198, a novel potent modulator of P-glycoprotein-mediated multidrug resistance. Anticancer Res 1995;15:811-4.
27. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271-7.
28. Demmer A, Dunn T, Hoof T, Kubesch P, Tümmler B. Competitive inhibition of photoaffinity labeling of P-glycoprotein by anticancer drugs and modulators including S9788. Eur J Pharmacol 1996;315:339-43.
29. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg ACLM, Schinkel AH, vande Vijver ML, Scheper RJ, Schellens JHM. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-64.
30. Busche R, Tümmler B, Riordan JR, Cano-Gauci DF. Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug-resistance. Mol Pharmacol 1989;35:414-21.
31. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley R. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
32. 125I]-LY475776: Evidence of a major binding site in the COOH-proximal membrane spanning domain. J Biol Chem 2002 May 28 [epub ahead of print].
33. Ren XQ, Furukawa T, Aoki S, Nakajima T, Sumizawa T, Haraguchi M, Chen ZS, Kobayashi M, Akiyama S. Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J Biol Chem 2001;276:23197-206.
34. Loe, DW, Almquist KC, Deeley, RG, Cole SPC. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996;271:9675-82.
35. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 1999;126:681-8.
36. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper RJ, Borst P. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 1998;188:797-808.